Clinical Trial

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will test an experimental drug called KQB198 in combination with imatinib. The goal is to determine if this combination is safe and tolerable and assess how effective the combination is at treating GIST. Imatinib has been approved by the FDA for the treatment of different types of cancer including GIST.
Protocol Amendment History 3 changes
notable Trial sites expanded: 8 -> 16 locations 2026-07-09
notable Trial sites expanded: 1 -> 8 locations 2026-05-20
critical Recruitment opened 2026-04-18
Trial Details
NCT Number NCT07406633
Lead Sponsor Kumquat Biosciences Inc.
Conditions GIST - Gastrointestinal Stromal Tumor, GIST, GIST Metastatic Cancer, Gastro Intestinal Stromal Tumour, Gastrointestinal Tumors
Enrollment 46 participants
Start Date 2026-06-23
Primary Completion 2027-10 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-10